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1. Introduction  
Ulcerative colitis (UC) as well as Crohn’s disease (CD) is one of the major inflammatory 
bowel diseases (IBD). Although genetic (1), infectious (2), and immunological (3, 4) factors 
have been reported to be involved in the pathogenesis of UC, the precise etiology remains 
unclear. UC is now diagnosed based on clinical, radiologic, endoscopic and 
histopathological findings. Thus, biomarkers for UC have been vigorously explored to 
diagnose UC accurately and non-invasively. The most clinically useful biomarker for UC at 
present is perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA) which is detected 
in 50-80% of UC patients (5). However, p-ANCA is also detected in 10-40% of CD patients, 
30-80% of patients with microscopic polyangiitis, 30-75% of patients with Churg-Strauss 
syndrome and 50% of patients with rapid progressive glomerulonephritis (5-7). A more 
sensitive and specific biomarker for UC should be established.   
Recently, there have been great advances in proteomics, the science dealing with the 
comprehensive analysis of protein expression. Proteomics have been applied to search of 
biomarkers in various diseases (8-10). In this paper, we introduced proteomic studies which 
explored biomarkers for UC by analyzing proteins in various clinical samples such as sera, 
peripheral blood mononuclear cells (PBMCs) and colonic mucosa. The comprehensive study 
can detect unexpected and sometimes novel molecules as a biomarker, which may also lead 
to elucidation of the pathogenesis of UC. 
1.1 Representative methods for proteomics 
As an assembly of genes is called as genome (gene + ome), an assembly of proteins is named 
as proteome (protein + ome). An assembly of low molecular proteins (peptides) is 
specifically called as peptidome (peptide + ome) (11). Proteomics are the study to 
comprehensively analyze proteome. There are two major methods for proteomics, 2-
dimensional electrophoresis (2DE) and shotgun method (Fig.1).  
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A. 2-dimensional electrophoresis (2DE) 
 
Extraction of whole proteins from cells or tissue 
 ↓ 
Isoelectric focusing 
 ↓ 
Sodium dodecyl sulfate-polyaclylamide gel electrophoresis (SDS-PAGE) 
↓ 
Detection of individual proteins as spots 
 ↓ 
Comparison of individual protein spot intensity between disease A and disease B 
 ↓  
Cut out the gel of the protein spots of interest 
 ↓ 
In gel digestion of the proteins by a protease 
 ↓ 
Identification of the proteins by mass spectrometry (MS) and protein database search 
 
 
B. Shotgun method 
 
Extraction of whole proteins from cells or tissue 
 ↓ 
Digestion of the mixture of proteins with a protease 
 ↓ 
Fractionating the obtained peptides by liquid chromatography 
 ↓ 
Analysis of individual peptides by MS/MS method to identify the original proteins 
 
Fig. 1. Representative methods for proteomics. 
The outlines of 2DE and shotgun method are described 
2DE is the method to separate cell- or tissue-derived proteins into protein spots by 
isoelectric focusing and subsequent sodium dodecyl sulfate-polyaclylamide gel 
electrophoresis (SDS-PAGE) (Fig.2). After the 2DE, protein spots of interest are cut out, and 
the proteins contained in the spots are identified by mass spectrometry (MS). Both matrix-
assisted laser desorption/ionization time-of-flight mass spectrometer (MALDI-TOF/MS) 
and liquid chromatography-mass spectrometer (LC-MS) are mainly used for the 
identification. One advantage of 2DE is to visualize the proteome of targeted cells or tissue 
as protein spots. A representative case is 2-dimensional differential image gel 
electrophoresis (2D-DIGE) which displays 2 kinds of proteome with different fluoresceines 
on the same gel (9). 2D-DIGE can visualize and compare proteome of two different samples, 
for examples, between a patient and a healthy donor, and before and after treatment with a 
drug. The other advantage of 2DE is to detect at least a part of the difference of post-
translational modification, amino acid mutation, and isotypes of one protein as different 
spots. Disadvantages of 2DE are that it is laborious requiring many manual procedures, and 
that number of detectable proteins is limited because proteins with low expression levels 
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and with extremely high or low molecular weights/isoelectric points are not visualized and 
separated, respectively. However, automation of 2DE has been recently developed, and use 
of a longer isoelectric focusing gel has increased number of detected proteins to achieve 
more comprehensiveness. 
 
 
Fig. 2. 2DE analysis of a UC patient. 
PBMCs were obtained from patients with UC, CD, and from a healthy subject, and proteins 
were extracted from the cells to be separated by 2DE. Representative results of a UC patient 
(A), a CD patient (B), and a healthy subject are shown. pI, isoelectric points; MW, molecular 
weights 
In the shotgun method, mixture of proteins extracted from cells or tissue is digested with a 
protease. When protein profiles of several disease groups are compared, proteins are 
sometimes labeled by isotopes such as iTRAQ and ICAT. The obtained peptide mixture was 
fractionated by liquid chromatography (LC) to be finally analyzed by MS/MS method (LC-
MS/MS). To fractionate minutely, 2D-HPLC is useful, for example, using a combination of 
strong cation exchange column and reverse-phase column. Surface enhanced laser 
desorption/ionization (SELDI)-TOF/MS is also used, in which proteins/peptides are 
trapped by radicals and molecules immobilized on protein chips to be directly measured by 
the MS system. The shotgun method has advantages to detect proteins with low expression 
levels, to achieve high comprehensiveness because of no limitation of isoelectric points, 
molecular weights, and hydrophilicity, and to automatize the procedures from fractionation 
to mass spectrometry. However, the proteome is not visualized, and nature of the original 
proteins remains unknown in this method.  
1.2 Discovery of biomarkers for UC  
Proteomic studies using sera, PBMCs, and colonic mucosa have found biomarker candidates 
for UC by comparison of UC, CD, other colitis, and healthy condition. Comprehensive 
analysis of a number of proteins makes multivariate analysis possible, which raises not only 
one protein but a combination of multiple proteins as a biomarker for UC. 
2. Serum proteomics 
A serum sample is one of the most frequently used clinical samples, which is obtained with 
low invasiveness. It contains a number of proteins which are physiologically and 
pathologically important. Serum samples would be an excellent source for the surveillance 
of biomarker candidates.  
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As a conventional proteomic study using MALDI-TOF/MS, Nanni et al analyzed serum 
protein profiles of UC patients, CD patients, and healthy subjects (12). The profiles of 20 
peptides extracted based on hydrophobic interaction completely classified all the cases into 
the original three groups, and UC was predicted with 96.3% prediction ability by cross 
validation of the classification model. In this study, the 20 peptides were not identified. In 
contrast, three studies analyzing serum proteins by SELDI-TOF-MS identified the biomarker 
candidates (Table 1) (13-15). Subramanian et al analyzed sera from UC and CD patients, and 
detected 12 discriminative peaks with both specificity and sensitivity of approximately 95% 
(13). Six out of the 12 proteins were identified, including inter alpha trypsin inhibitor 4, 
apolipoprotein C1, and platelet activated factor 4 variants. Meuwis et al generated 
classification models by multivariate analysis, whose sensitivity and specificity to 
discriminate UC from CD were approximately 80% and 90%, respectively (14). Four 
biomarkers with important diagnostic values were identified as platelet aggregation factor 4 
(PF4), myeloid related protein 8 (MRP8), fibrinopeptide A (FIBA), and haptoglobin α2 
(Hpα2). Kanmura et al selected human neutrophil peptides 1-3 (HNP 1-3) from the 27 
proteins with significantly different concentration between UC and healthy sera (15). In a 
larger cohort, concentration of HNP 1-3 were significantly higher in active UC patients 
compared to that in UC patients in remission, CD patients, patients with infectious colitis, 
and healthy subjects. Levels of HNP 1-3 decreased after corticosteroid therapy in responders 
for the drug, whereas the levels were not changed in non-responders. As a new method, 
Haas et al analyzed serum samples from UC and CD patients by Fourier Transform Near-
Infrared Spectroscopy (FT-NIR) (16). The cluster and Artificial Neural Networks (ANN) 
analyses of the results correctly identified 80% and 69.8% of UC, respectively, suggesting a 
usefulness of this technology. In addition, a pilot study compared sera between corticosteroid-
resistant and -responsive UC patients, and detected 19 proteins with significantly different 
concentration, which may predict response to the treatment in UC (17). 
Proteomics include studies using various kinds of protein arrays. Kader et al used antibody 
arrays containing 78 cytokines, growth factors and soluble receptors to screen sera from UC 
and CD patients (18). In UC, only IL-12p40 was significantly upregulated in the remission 
stage compared to in the active stage (p<0.02). On the other hand, in CD, significantly 
elevated levels of 4 cytokines including IL-12p40 were found in the remission stage 
compared to in the active stage (p<0.01). The other 3 cytokines were placenta-derived 
growth factor, IL-7, and TGF-β1. In another study using protein arrays, Escherichia coli-
derived proteome was served to screen serum antibodies (19). A set of antibodies 
distinguished UC patients from healthy subjects with 66% accuracy (p<0.05). The other 
antibody set distinguished UC patients from CD patients with 80% accuracy (p<0.01). The 
latter set consists of only two kinds of antibodies which recognized YidX and Frv X, 
suggesting that immune reaction to the 2 proteins from E. coli would be useful for 
discrimination of UC from CD.  
It seems to be difficult to find serum autoantibodies which are more powerful than p-ANCA 
even using proteomic techniques. Vermeulen et al analyzed serum autoantibodies against 
commercial human protein arrays (20). 75 proteins reacted more strongly with sera from 
IBD patients than those from healthy subjects, while 88 proteins showed the opposite 
pattern. One of the identified proteins as an autoantigen for IBD was pleckstrin homology-
like domain, family A, member 1 (Phla1). In a large cohort, 42.8% of the UC patients, 50.0% 
of the CD patients, (taken together, 46% of the IBD patients), 33.3% of the patients with non-
IBD gastrointestinal diseases, and 28.7% of the healthy subjects were positive for the anti-
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Phla1 antibodies. Thus, discriminative power between UC and CD, and IBD and controls 
remained low. The same research group also analyzed serum autoantibodies against α-
enolase in IBD by a classic proteomic approach (21). The anti-α-enolase antibodies were 
detected in 49.0% of the UC patients, 50.0% of the CD patients, 37.8% of the patients with 
autoimmune hepatitis, 34.0% of the patients with ANCA-positive vasculitis, and 31.0% of the 
patients with the other gastrointestinal diseases, showing the only limited diagnostic value. 
 
References Samples Methods Identified proteins 
Subramanian  
et al (13) 
sera SELDI- 
TOF MS 
inter alpha trypsin inhibitor 4  
apolipoprotein C1  
platelet activated factor 4 variants 
Meuwis et al 
(14)  
sera SELDI- 
TOF MS 
platelet aggregation factor 4 (PF4)  
myeloid related protein 8 (MRP8)  
fibrinopeptide A (FIBA)  
haptoglobin α2 (Hpα2) 
Kanmura  
et al (15) 
sera SELDI- 
TOF MS 
Human neutrophil peptide (HNP) 1-3 
Kader et al 
(18) 
sera antibody 
array 
IL-12p40 (upregulated in the remission stage 
than in the active stage in UC)  
Chen et al  
(19) 
sera E. coli- 
protein 
array 
YidX  
Frv X 
Vermeulen  
et al (20) 
sera Human 
protein 
arrays 
autoantibodies against pleckstrin homology-
like domain, family A, member 1 (Phla1) 
Vermeulen  
et al (21) 
sera  autoantibodies against α-enolase 
Hatsugai  
et al (9) 
PBMCs 2DE, 
MALDI-
TOF MS 
cyclophilin A (PPIA)   
protein S100-A9 (S100A9) 
peroxiredoxin-2 (PRDX2) 
carbonic anhydrase 2 (CA2) 
β-actin (ACTB) 
annexin A6 (ANXA6) 
α/β Hydrolase domain-sontaining protein 
14B (ABHD14B) 
Table 1. Blood biomarker candidates for UC 
3. Proteomics of PBMCs  
PBMCs, relatively easily prepared from the peripheral blood, contain a number of proteins 
different from serum proteins. Because UC is considered as an autoimmune disease, 
analysis of PBMCs which include lymphocytes and monocytes is useful not only for the 
biomarker surveillance but also for the elucidation of the pathogenesis of UC. However, 
little has been known about the protein profile of PBMCs in UC.  
We comprehensively analyzed proteins in PBMCs from UC, focusing on discrimination of 
UC from CD (9). PBMC-derived proteins from UC patients, CD patients, and healthy 
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subjects were separated by 2DE, and intensity of individual protein spots was subjected to 
multivariate analysis to generate differential diagnostic models between UC and CD. As a 
result, 547 protein spots were detected in the 2DE results. Two diagnostic models were 
generated using intensity of selected 276 protein spots and further selected 58 protein spots, 
both of which completely discriminated between UC and CD (sensitivity and specificity 
were 100% in these models). Eleven out of the 58 protein spots were identified, which were 
functionally related to inflammation (cyclophilin A, PPIA; protein S100-A9, S100A9), 
oxidation/reduction (peroxiredoxin-2, PRDX2; carbonic anhydrase 2, CA2), cytoskeleton (β-
actin, ACTB), endocytotic trafficking (annexin A6, ANXA6), and transcription (α/β 
Hydrolase domain-sontaining protein 14B, ABHD14B). Interestingly, the PBMC protein 
profiles were useful for prediction of disease activity in the UC and the CD patients, and 
prediction of severity and responses to treatments in the UC patients. Especially, some 
clinical parameters were predicted by intensity of a few protein spots, for example, intensity 
of only 2 protein spots for disease activity of the UC. Proteins associated with the activity of 
UC may be extremely restricted. PBMC protein profile would be a potent biomarker for 
differential diagnosis of UC from CD, and investigation of the proteins contributing to the 
discrimination may elucidate the different pathophysiology of UC from CD. 
As an antigen-specific model, an IBD model was established using male SD rats by colonic 
administration of trinitrobenzene sulfonic acid (TNBS) in 50% ethanol (22). Lymphocyte-
derived protein profiles from the model rats and the control rats receiving 50% ethanol were 
compared by 2DE and MALDI-TOF/MS, which revealed different expression of 26 proteins 
(17, upregulated; and 9, downregulated) included regulators of the cell cycle and cell 
proliferation, signal transduction factors, apoptosis-related proteins and metabolic enzymes. 
4. Proteomic analyses of colonic mucosa from UC 
Proteomic analysis of colonic mucosa has demonstrated multiple biomarker candidates. The 
analyses using clinical samples of the disease-affected sites may highly contribute to 
elucidation of the pathophysiology of UC, indicating functional difference of various 
proteins from the other gastrointestinal diseases. 
Comparing protein profiles between the UC-affected mucosa and normal mucosa both from 
UC patients by 2DE and subsequent LC-MS, protein spots showing higher intensity in the 
UC-affected mucosa than in the normal mucosa were identified (23). They were 
protocadherin, α-1 antitrypsin, tetratrico-peptide repeat domains, caldesmon, and mutated 
desmin, associated with inflammation and cell repair (Table 2). Especially, a mutated form 
of desmin was detected in all the examined UC-affected mucosa, suggesting its potential as 
a UC biomarker. Another study comparing colonic mucosa from UC patients and healthy 
subjects by 2DE and MALDI-TOF/MS showed 13 downregulated and 6 upregulated 
proteins in UC (24), which were involved in mitochondrial function (heat shock protein 70, 
HSP70; HSP60; H+-transporting two sector ATPase, ATP5B; prohibitin, PHB; malate 
dehydrogenase, MDH2; voltage-dependent anion-selective channel protein 1, VDAC1; 
thioredoxin peroxidase 1, PRDX1; PRDX2), energy generation (ATP5B, MDH2, 
triosephosphate isomerase), cellular antioxidants (PRDX1; PRDX2; selenium binding protein 
1, SELENBP1), and stress-response (HSP70, HSP60, PRDX1, PRDX2, PHB, VDAC1). 
Aberrant activation of nuclear factor of activated T cell (NFAT), and ectopic expression of 
tumor rejection antigen 1 and poliovirus receptor related protein 1 were detected in the UC-
affected colonic mucosa.  
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References Samples  Methods Identified proteins 
Fogt et al (23) colonic 
mucosa 
2DE, LC-
MS 
protocadherin, α-1 antitrypsin,  
tetratrico-peptide repeat domains, 
caldesmon, mutated desmin 
Hsieh et al 
(24) 
colonic 
mucosa 
2DE, 
MALDI- 
TOF/MS 
heat shock protein 70 (HSP70), HSP60,  
H+-transporting two sector ATPase (ATP5B), 
prohibitin (PHB), malate dehydrogenase 2 
(MDH2), voltage-dependent anion-selective 
channel protein 1 (VDAC1), thioredoxin 
peroxidase 1 (PRDX1), PRDX2, 
triosephosphate isomerase,  
selenium binding protein 1 (SELENBP1), 
nuclear factor of activated T cell (NFAT), 
tumor rejection antigen 1,  
poliovirus receptor related protein 1 
Shkoda et al 
(25) 
colonic 
mucosa 
2DE, 
MALDI- 
TOF/MS 
programmed cell death protein 8,  
annexin 2A 
(Both increased in inflamed regions) 
Shih et al (26) colonic 
mucosa 
2DE, 
IHC 
Translocation of NFAT2 into nuclei 
Berndt et al 
(27) 
T cells in 
colon 
MELC Colocalization of NF-kB and poly (ADP-
ribose)-polymerase 
Naito et al 
(30) 
mouse 
intesitinal 
mucosa 
2DE, 
MALDI- 
TOF/MS 
3-Hydroxy-3- methlglutaryl-coenzyme A 
synthase 2, serpin b1a, protein disulfide- 
isomerase A3, PRDX6, vimentin 
Table 2. Biomarker candidates for UC identified from colonic mucosal cells 
Comparison with colonic mucosal proteins between UC and CD revealed their specific 
characters of UC and common features to IBD (25-27). Intestinal epithelial cells (IECs) from 
patients with UC, CD, and colon cancer, analyzed by 2DE and MALDI-TOF/MS, showed 21 
protein spots with at least 2-fold change between inflamed tissue from the IBD (UC and CD) 
patients and non-inflamed tissue from the patients with colonic cancer (25). The identified 
proteins were functionally related to signal transduction, stress response, and energy 
metabolism. Specifically, Rho-GDP dissociation inhibitor α, which inhibits cell cycle 
progression, was upregulated in IBD and sigmoid diverticulitis, possibly involving with the 
destruction of IEC homeostasis under the condition of chromic inflammation. On the other 
hand, 40 proteins were significantly altered between inflamed and noninflamed regions in 
the UC patients. The proteins included programmed cell death protein 8 and annexin 2A, 
both of which were increased in the inflamed regions. In addition, localization of the 
proteins may indicate the pathophysiological difference of UC and CD (26, 27). NFAT2, 
increased in the UC-affected colon tissue in the 2DE results, was specifically translocated 
into nuclei of the UC colonic mucosa, whereas NFAT2 was located exclusively in cytoplasm 
in the normal and the CD mucosa (26). A modified proteomic method, Multi-Epitope 
Ligand Cartography (MELC), showed that only CD4+ T cells co-expressing NF-kB were 
caspase-8+ and poly(ADP-ribose)-polymerase+ in the UC colonic mucosa (27). The 
colocalization of NF-kB+ and poly(ADP-ribose)-polymerase+ would be the base motif that 
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discriminates UC from CD. Interestingly, the number of CD4+CD25+ T cells was elevated 
only in the UC mucosa, but not in the CD mucosa and the normal mucosa from patients 
with colonic cancer, suggesting the specific activation of regulatory T cells in UC.  
Other modified methods including cellular or subcellular analyses have brought useful 
information (28, 29). Effects of inflammatory cytokines of IFNγ, IL-1β, and IL-6 on IBD were 
investigated human adenocarcinoma cells by 2DE and MALDI-TOF/MS (28). Tryptophanyl 
tRNA synthetase, indoleamine-2,3-dioxygenase (IDO), heterogenous nuclear 
ribonucleoprotein JKTBP, IFN-induced p35, proteasome subunit LMP2, and arginosuccinate 
synthetase were identified as the cytokine-regulated proteins. Overexpression of IDO in 
IECs was found in the UC and CD mucosa, but not in the diverticulitis and normal mucosa, 
suggesting that the specific response of IDO to the inflammatory cytokines may be a 
character of IBD. As a subcellular fractionation analysis, expression levels of 5’ nucleotidase 
(plasma membrane), malate dehydrogenase (mitochondria), catalase (peroxisomes), LDH 
(ER), N-acetyl-β-glucosaminidase (lysosomes), and neutral-α-glucosidase (ER) in rectal 
biopsy homogenates from the UC, CD, and non-rectal CD patients were assayed (29). 
Reduction of both cytosolic and particulate N-acetyl-β-glucosaminidase was found in the 
UC patients, whereas a selective reduction in particulate activity was found in the non-rectal 
CD patients, demonstrating lysosomal alterations in these diseases. 
IECs from UC or IBD model mice have been analyzed by proteomics (30-33). Intestinal 
mucosa from a UC mouse model, made by oral administration of 8.0% dextran sodium 
sulfate, was analyzed by 2DE and MALDI-TOF/MS (30). Comparison of mucosa from the 
UC model with that from normal mice revealed 7 altered protein spots. Five proteins were 
identified from the spots, which were 3-Hydroxy-3-methlglutaryl- coenzyme A synthase 2, 
serpin b1a, protein disulfide-isomerase A3, PRDX6 and vimentin. To investigate response of 
IECs against a pathogen, Caco-2 IEC line was co-cultured with Enteropathogenic E. coli 
(EPEC) to be injected the bacterial proteins through bacterial type III secretion system 
(TTSS) (31). Among 2,090 host proteins identified by LC-MS, 264 proteins (approximately 
13%) were differentially expressed between WT EPEC-cocultured IECs and TTSS-deficient 
EPEC-cocultured IECs, suggesting that host proteins were potentially involved in EPEC-
induced colitis. 
Based on an interesting idea that endoplasmic reticulum (ER)-mediated stress responses in 
IECs may contribute to chronic intestinal inflammation, IECs from Enterococcus faecalis-
monoassociated IL-10-deficient mice and WT mice were analyzed by 2DE and MALDI-
TOF/MS (32). Increased expression of glucose-regulated ER stress protein (grp)-78 was 
found in the IL-10-deficient mice. In human, the increased expression of grp-78 was also 
found in the inflamed colonic tissue from patients with UC, CD and sigmoid diverticulitis. 
IL-10 was found to inhibit inflammation-induced ER stress response by modulating nuclear 
recruitment of activating transcriptional factor (ATF)-6 to the grp-78 gene promoter. 
Another interesting idea is raised from the field of neutrinogenomics, in which 
environmental factors would contribute to the chronic intestinal inflammation in the 
genetically susceptible hosts (33, 34). In this respect, TNFDeltaARE/WT mice were 
prepared, which showed impaired regulation of TNFα synthesis by deletion of an AU-rich 
motif in the 3’-untranslated region of the TNF gene (35). WT and TNFDeltaARE/WT mice 
were fed with adequate and low amount of iron, and the adequate iron-fed 
TNFDeltaARE/WT mice were found to develop severe ileal inflammation. Comparison of 
IEC-derived proteins between adequate iron-fed WT and TNFDeltaARE/WT mice 
(inflamed conditions), and that between adequate iron- and low iron-fed 
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TNFDeltaARE/WT mice (absence of inflammation), by 2DE and MALDI-TOF/MS showed 
4 contrarily regulated proteins including aconitase 2, catalase, intelectin 1, and 
fumarylacetoacetate hydrolase (FAH). These proteins are associated with energy 
homeostasis, host defense, oxidative, and ER stress responses.  
5. Prediction of colorectal cancer associated with UC 
UC shows an increased risk of colorectal cancer compared to other inflammatory intestinal 
diseases. In UC patients, occurrence of colorectal cancer is periodically examined by 
colonoscopy throughout their lives. To avoid this invasive and expensive examination, a 
biomarker which predicts occurrence of colorectal cancer in UC will be useful. Further, 
although UC-associated colon cancer is known to develop from dysplastic lesions caused by 
chronic inflammation, the molecular mechanism how inflammation leads to carcinogenesis 
should be elucidated.  
Brentnall et al analyzed protein profiles of epithelium from normal colon, nondysplastic 
colon of UC patients without dysplasia (UC nonprogressors), nondysplastic colon of UC 
patients with high grade dysplasia or cancer (UC progressors), and high grade dysplastic 
colon of UC progressors by LC-MS subsequent to strong cation exchange (36). Proteins 
related to mitochondria, oxidative activity, and calcium-binding proteins were associated 
with the neoplastic progression in UC. In the early and late stages, Sp1 and c-myc may play 
roles in UC neoplastic progression, respectively (Table 3). Carbamoyl-phophate synthase 1 
(CPS1) and S100P were overexpressed in nondysplastic colon tissue from the UC 
progressors. The overexpression may be useful for the prediction of dysplasia in UC.  
In another study from the same research group, differently expressed proteins between 
nondysplastic and dysplastic tissue from the UC progressors were detected by LC-MS (37). 
They were mitochondrial proteins, cytoskeletal proteins, RAS superfamily, proteins related 
to apoptosis and metabolism, suggesting their importance in the early stages of neoplastic 
progression in UC. Among such proteins, both TNF receptor-associated protein 1 (TRAP1) 
and CPS1 were increased in nondysplastic and dysplastic tissue in the UC progressors than 
in the nonprogressors. Rectal CPS1 staining predicts dysplasia or cancer in the colon with 
87% sensitivity and 45% specificity, indicating its feasibility as a biomarker to predict colonic 
dysplasia or cancer. On the other hand, comparison of UC-associated and sporadic colon 
cancer cell lines by 2DE and LC-MS showed that the expression of heat shock protein 
(HSP47) was significantly higher in UC-associated colon cancers, the increase of which was 
correlated to the progression of neoplastic lesions (38). HSP47 was co-expressed with type I 
collagen in the cytoplasm, and both of them were released from culture cells into the 
medium, suggesting the possibility of HSP47 as a biomarker for UC-associated cancer. 
Analysis of colonic mucosa by MELC study showed significant increase of NF-kB+ HLA-
DR+ cells in CD4+ and CD8+ cell populations in UC patents and patients with colorectal 
cancer compared to healthy subjects (39). This suggested increase of activated T cells and an 
altered antigen presentation. In the UC group, NF-kB+ cells were significantly increased in 
CD45RO+ cell populations, but not in CD45RA+ cell population, suggesting the activation 
in memory T cells. CD4+CD25+NF-kB+ cells were also specifically increased in the UC 
group, which indicated the increase of regulatory T cells. The specific activation of such 
subpopulations of T cells would play protective roles in UC, and loss of the activation may 
play a role in the progression of colorectal cancer. In an animal model for UC, which was 
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established by repeatedly exposing B6 mice to dextran sodium sulfate (DSS), proteins in 
colonic mucosa were analyzed by 2DE and MALDI-TOF/MS (40). 38 protein spots were 
found to be differently expressed in colon tumors compared to normal colon, 27 of which 
were identified. They included glucose-regulated protein (GRP) 94, HSC70, emolase, PHB 
and transgelin. Transgelin was found to be significantly reduced in human colon tumors 
compared with adjacent nontumorous tissues, suggesting that low expression of this protein 
may be a candidate biomarker of colitis-associated colon cancer.  
 
References Samples  Methods Identified proteins 
Brentnall  
et al (36) 
colonic 
mucosa 
LC-MS Sp1, 
Carbamoyl-phophate synthase 1 (CPS1), S100P 
May et al  
(37) 
colonic 
mucosa 
LC-MS TNF receptor-associated protein 1 (TRAP1), 
CPS1 
Araki et al 
(38) 
colon 
cancer cell 
lines  
2DE, 
LC-MS 
heat shock protein (HSP47) 
Berndt et al 
(39) 
T cells in 
colon 
MELC (Increase of CD45RO+NFkB+ cells and 
increase of CD4+CD25+NFkB+ cells  
in UC than in colorectal cancer) 
Yeo et al (40) Mouse 
colonic 
mucosa 
2DE, 
MALDI- 
TOF/MS 
transgelin (GRP94, HSC70, enolase, PHB, and 
transgelin were differently expressed  
in colon tumors in the UC-model mice  
from those in normal colon) 
Table 3. Biomarker candidates to predict complication of colorectal cancer in UC 
6. Subproteomic analyses – metabolomics and other studies 
As subproteomic analyses, metabolomics which comprehensively analyze metabolites have 
been performed in IBD patients and also in UC model mice. Because metabolites are easily 
obtained from urine or fecal samples, use of biomarkers detected by metabolomics may be 
less-invasive compared to those derived from blood and colonic tissue. In addition to MS 
analysis, nuclear magnetic resonance (NMR) spectroscopy is frequently used in 
metabolomics. Metabolomics, which analyze different molecular profiles from proteomics, 
should also contribute to unraveling the pathophysiology of UC.  
Fecal extracts from patients with CD and UC were analyzed by 1H NMR spectroscopy (41). 
The levels of butyrate, acetate, methylamine, and trimethylamine were found to be lower in 
both diseases than in healthy subjects. The results may indicate changes of microbial 
community in gut. In contrast, elevated quantities of amino acids were demonstrated in 
both diseases, implying malabsorption caused by inflammation. Interestingly, the decreased 
amounts of amino acids and glycerol, and the increase of butyrate and acetate, in the feces of 
UC patients contributed to the discrimination of UC from CD (Table 4). A conventional 
metabolic analysis, in which utilization of n-butyrate, glucose, and glutamine in isolated 
colonic epithelial cells were evaluated, showed that oxidation of butyrate to CO2 and 
ketones was significantly suppressed in UC colonic mucosa compared to normal mucosa 
(42). The failure of n-butyrate oxidation in UC suggests that UC may be an energy-
deficiency disease of the colonic mucosa. To specifically distinguish UC from CD, 
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exoprotease activity was assayed using 2 synthetic peptides as substrates, which were 
fibrinopeptide A without the N-terminal alanine and complement 3f (43). The two peptides 
were spiked into serum samples from 3 UC patients, 3 CD patients, and 3 healthy subjects, 
and the metabolite pattern was analyzed by MALDI-MS and chemometric analysis. 
Although 100% discrimination of the UC patients from the CD patients and the healthy 
subjects was achieved, the diagnostic power should be verified with more number of 
subjects.  
 
References Samples  Methods Identified metabolites 
Marchesi  
et al (41) 
fecal 
extracts 
NMR decreased amounts of amino acids and 
glycerol, and increase of butyrate and acetate, 
compared to those in CD 
Roediger  
et al (42) 
IECs of 
colon 
Metabolic 
analysis 
decreased oxidation of butyrate to CO2 and 
ketones 
Table 4. Biomarker candidates for UC identified by metabolomics 
As an IBD model study, time course of urine metabolites from IL-10-deficient mice were 
compared with those from control mice by NMR analysis (44). Both groups initially had 
similar metabolic profiles, then diverged substantially with the onset of IBD. The levels of 
trimethylamine and fucose changed dramatically in 8wk IL-10-deficient mice, at the timeline 
of histological injury. In addition, bacterial signaling molecules involved in their 
communication may serve as potential biomarkers for IBD (45). Profiles of N-acyl 
homoserine lactones (AHLs), the chemical signaling molecules in Gram-negative bacteria, in 
saliva from healthy donors and patients with gastrointestinal disorders were analyzed by 
LC-MS. The levels of AHLs may correlate with the health status of subjects. 
7. Conclusion 
Novel approaches by proteomics and subproteomics for biomarker discovery of UC, 
including those of the complication of colorectal cancer, were introduced. Many proteins 
have been identified and considered to be candidates for UC biomarkers, however, most of 
them have not established, indicating the broad range of functional abnormality in UC. 
PRDX2, PHB, CPS1, and butyrate were identified in multiple different studies, suggesting 
their usefulness as a biomarker for UC or the associated colonic cancer. The candidate 
biomarkers should be validated with more number of patients with UC, CD, other control 
diseases, and healthy subjects. Even though simple and less-invasive biomarkers are 
desirable for clinical examination, if the biomarkers are sensitive and specific enough for the 
UC diagnosis, examination of colonic mucosa obtained by endoscopy and combination of 
multiple proteins as the biomarker are also acceptable. Further advances in these 
approaches would be useful to establish biomarkers for the accurate diagnosis and the 
disease course prediction, and may be useful to elucidate the complicated disease 
mechanisms of UC.  
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